Strides Pharma Science Share Price Today

Strides Pharma Science receives three USFDA remarks at Alathur facility

Strides Pharma Science received three observations from the USFDA after an inspection of its Alathur facility. The USFDA inspection covered the company's Alathur manufacturing site. No further details on the specific nature of the three remarks have been disclosed.

Strides Pharma Science receives USFDA EIR for Bengaluru facility with VAI status

Strides Pharma Science received a USFDA Establishment Inspection Report for its Bengaluru manufacturing facility with a Voluntary Action Indicated (VAI) classification, announced on August 19, 2026. The cGMP inspection was conducted from May 12 to May 20, 2026, initially resulting in a Form 483 with five observations, all of which were addressed by the company within the stipulated timeline. The VAI classification confirms formal closure of the inspection, with no mandatory corrective actions required, reinforcing the company's regulatory standing across its global manufacturing network.

Strides Pharma Science passes AGM resolutions on dividend, board appointments

Strides Pharma Science Limited completed its 35th AGM on August 14, 2026, with shareholders approving all six resolutions including FY26 financial statements, final dividend, and three board appointments. Promoter group participation exceeded 95% across all items, with total shareholder turnout reaching approximately 73% of outstanding shares.

Strides Pharma Science Q1FY27 PAT surges 56.7% on Pivot Path gain

Strides Pharma Science reported consolidated PAT of ₹1,655 million for Q1FY27, up 56.7% YoY, largely aided by a ₹742 million exceptional gain from Pivot Path. Excluding this, operational PAT grew 8%. Revenue expanded 13% to ₹12,654 million, with Ex-US markets growing 17%. The company reduced net debt by ₹119 million and saw its CARE rating upgraded to A+; Stable.

Strides Pharma Science Q4 Results: Earnings call audio available

Strides Pharma Science Limited disclosed the availability of its Q4FY26 earnings call audio on July 31, 2026. The session covered unaudited results for the quarter ended June 30, 2026, complying with SEBI LODR Regulations 30 and 46. Investors can access the recording on the company website for detailed insights into financial performance.

Strides Pharma Science Q1 Results: Net profit rises 16% YoY to ₹2,113 lakh

Strides Pharma Science posted a 16% YoY rise in Q1FY26 standalone net profit to ₹2,113.26 lakh. Revenue grew to ₹20,870.93 lakh, though it declined sequentially from Q4FY26 levels. Consolidated net profit was ₹2,090.90 lakh.